Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • Neuigkeiten
  • Über uns
  • Kontakt

Neuigkeiten 2009

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

AGENDIA - FDA Broadens Clearance for MammaPrint

17 Dezember 2009 – HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast…

Betreffend: Agendia

Gilde Healthcare Partners raises growth capital fund dedicated to healthcare services

9 Dezember 2009 – Utrecht, The Netherlands – Gilde Healthcare Partners (Gilde), a European private equity firm specializing in healthcare, today announced the launch of a new growth capital fund, Gilde Healthcare Services. The fund will invest in specialized clinics, providers of elderly care, prevention,…

SANTARIS PHARMA - New data show breakthrough microRNA-targeted therapy

3 Dezember 2009 – SPC3649 successfully inhibits miR-122, a microRNA important for hepatitis C viral replication, thereby significantly reducing hepatitis C virus in the bloodstream in chimpanzees chronically infected with the hepatitis C virus Hoersholm, Denmark/San Diego, California — A study published…

Betreffend: Santaris Pharma

ABLYNX will receive further milestone payments of EUR 3 million as part of its alliance

2 Dezember 2009 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it will receive further milestone payments totalling €3 million from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of Nanobodies®. Ablynx will now have…

Betreffend: Ablynx

AMT Announces Management Changes in light of refocused strategy

2 Dezember 2009 – Amsterdam – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a number of management changes. Piers Morgan (age 43) has been appointed Chief Financial Officer, effective December 1, 2009. Hans Preusting, PhD (age 47), Director…

INNATE PHARMA initiates collaboration with Celgene

18 November 2009 – Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene's REVLIMID® Growing body of evidence in hematological malignancies supports REVLIMID® enhanced…

Betreffend: Innate Pharma

BG MEDICINE and Abbott announce a development and commercialization agreement for galectin-3 biomark

17 November 2009 – Abbott (NYSE: ABT) and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry…

Betreffend: BG Medicine

Symphogen Opens US Operations in Princeton, New Jersey

3 November 2009 – -US Subsidiary Supports Expanding Opportunities for Symphogen’s Novel Antibody Pipeline and Discovery and Expression Platforms- COPENHAGEN, Denmark and PRINCETON, NJ - Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax,…

Betreffend: Symphogen

FlowCardia, Inc. expands treatment options for patients with chronic total occlusion

21 Oktober 2009 – SUNNYVALE, Calif. — FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced the U.S. launch of the Over the Wire (OTW) delivery platform for the CROSSER® 14S and CROSSER® 14P peripheral CTO…

Betreffend: Flowcardia

Ablynx receives milestone payments from Boehringer Ingelheim and Wyeth

9 Oktober 2009 – HENT, Belgium - Ablynx [Euronext Brussels: ABLX], today announced that it will receive milestone payments totalling €3 million from Boehringer Ingelheim triggered as part of its strategic alliance for the development and commercialisation of Nanobodies®. This is the second time Ablynx…

Betreffend: Ablynx

FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance

6 Oktober 2009 – SUNNYVALE, Calif. — FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), has launched the FlowMate Injector, which dramatically simplifies central lumen crossing of CTOs using the CROSSER CTO Recanalization…

Betreffend: Flowcardia

GILDE HEALTHCARE II invests in mtm laboratories AG

5 Oktober 2009 – HEIDELBERG, Germany -- mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its…

Betreffend: mtm laboratories

AMT Appoints New Chief Executive Officer

24 September 2009 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in human gene therapy, announced today the appointment of Jörn Aldag as its new Chief Executive Officer, starting October 5. Mr. Aldag has a strong record of accomplishments in the life sciences…

Agendia raises EUR 16.6 million (USD 23 million) in series E financing

22 September 2009 – HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a world leader in molecular cancer diagnostics, today announced the successful closing of a EUR 16.6 million (USD 23 million) Series E investment. The round was subscribed by an international syndicate of both new and…

Betreffend: Agendia

New collaborations and breakthrough advancements in RNA-based drug development programs

16 September 2009 – Denmark-based Santaris Pharma A/S appoints leading RNA industry expert Art Levin Ph.D. as President of US operations  and Chief Development Officer       Utilizing its proprietary RNA chemistry - Locked Nucleic Acid (LNA) –and Drug Discovery Engine, the US subsidiary aims to foster…

Betreffend: Santaris Pharma

Pieris AG enters into Anticalin Collaboration with Allergan, Inc.

15 September 2009 – Germany - Pieris AG announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris’ proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development with a goal of developing agents for…

Betreffend: Pieris Pharmaceuticals Inc.

Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines

24 August 2009 – Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic…

Betreffend: Santaris Pharma

Gilde Healthcare Partners leads EUR 8 million series B financing in Profibrix B.V.

24 August 2009 – LEIDEN, THE NETHERLANDS and SEATTLE, WA - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a EUR 8 million series B investment. The financing round was led by new investor Gilde Healthcare…

Betreffend: ProFibrix

ABLYNX Announces positive Phase I results for subcutaneous administration

18 August 2009 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced the positive results from its double-blind, randomized, placebo-controlled, single and multiple dose Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets…

Betreffend: Ablynx

Symphogen Appoints Adriann Sax Chief Business Officer

17 August 2009 – Seasoned Executive will Drive Business Development Efforts for Antibody Discovery and Expression Platforms COPENHAGEN, Denmark - Symphogen A/S today announced that Adriann Sax has joined the company’s management team as Chief Business Officer. Ms. Sax brings to Symphogen extensive…

Betreffend: Symphogen

Innate Pharma reports positive phase IIa in type C viral hepatitis

29 Juli 2009 – Marseilles, France - Innate Pharma (Euronext Paris: FR0010331421 – IPH) reports positive results for its first Phase IIa clinical trial with IPH 1101 (a small-molecule ?? T cell agonist) in patients with type C viral hepatitis (“HCV”). In this open-label trial, two injections of IPH…

Betreffend: Innate Pharma

BG MEDICINE and Humana Enroll More Than 6,800 Participants in BioImage Study

7 Juli 2009 – Humana Health-Plan Members in Chicago and South Florida Volunteered to Participate in Study LOUISVILLE, Ky. & WALTHAM, Mass - Imagine if doctors could easily detect the conditions that cause many heart attacks or strokes – in time to prevent the life-threatening attacks. BG Medicine…

Betreffend: BG Medicine

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

24 Juni 2009 – On June 24, 2009 Conatus Pharmaceuticals Inc. (San Diego, USA) announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom…

Betreffend: Conatus Pharmaceuticals

Agendia's Breast Cancer Recurrence Test MammaPrint Included

23 Juni 2009 – International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast…

Betreffend: Agendia

Chroma Therapeutics completes £15 million Series D financing

23 Juni 2009 – Oxford – Chroma Therapeutics Limited, a UK based biotechnology company focused on small molecule cancer and inflammation therapeutics, announces it has completed a £15 million Series D financing round. Chroma will use the funds to develop its aminopeptidase inhibitor, tosedostat (CHR-2797)…

Betreffend: Chroma Therapeutics

Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline

23 Juni 2009 – Chroma Therapeutics Limited and GlaxoSmithKline form alliance to develop novel macrophage-targeted drugs Oxford and London, UK – Chroma Therapeutics Limited and GlaxoSmithKline, through its Center of Excellence for External Drug Discovery (CEEDD), (LSE: GSK) announced today a collaboration…

Betreffend: Chroma Therapeutics

AMT - Glybera(TM) Shows Long-Term Health Benefits

18 Juni 2009 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today new data showing that a one-time administration of its lead product GlyberaTM results in significant long-term health benefits. Long-term follow-up…

Acacia Pharma initiates Phase II study with APD405 in post-operative nausea & vomiting (PONV)

8 Juni 2009 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, announces the initiation of a Phase II study of its lead compound, APD405, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant…

Betreffend: Acacia Pharma

SANTARIS - LNA-based HIF-1 alpha inhibitor shows early signs of clinical benefit

4 Juni 2009 – Copenhagen, Denmark - Santaris Pharma today announced that the cancer drug EZN-2968 – an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S – was well tolerated and showed early signs of clinical benefit in previously treated cancer patients…

Betreffend: Santaris Pharma

AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

28 Mai 2009 – AMSTERDAM - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-021 for the treatment of acute intermittent porphyria…

Agendia Opens CLIA-Registered U.S. Genomics Laboratory Agendia Increases U.S. Footprint

26 Mai 2009 – HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The laboratory is fully-licensed and compliant with the Clinical Laboratory…

Betreffend: Agendia

IDEA reports results from a prospective 3 years phase III study of Diractin®

2 April 2009 – Munich, Germany – IDEA AG today announced positive results of  a long-term, open-label, Phase III study in joint-pain, musculoskeletal pain (including lower back pain), stiffness, or soft tissue inflammation, presented at the 9th European Congress on Clinical and Economic Aspects…

Acacia Pharma initiates Phase IIa study with APD209 in cancer cachexia patients

31 März 2009 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, announced the initiation of a Phase IIa study of its product APD209 to treat cachexia in cancer patients. APD209 has been designed to target specific problems experienced…

Betreffend: Acacia Pharma

BG Medicine Inc. launches Galectin-3 Website and Commences Galectin-3 Assay Service

31 März 2009 – WALTHAM, Mass. – (BUSINESS WIRE) - BG Medicine Inc. (BGM), a developer of novel, biomarker-based diagnostic products, today announced the launch of the Galectin-3 Website (www.galectin-3.com) which will provide an array of research materials associated with galectin-3. Galectins…

Betreffend: BG Medicine

SYMPHOGEN and Origen Collaborate to Produce Transgenic Chicken for generation

6 März 2009 – COPENHAGEN, Denmark and EMERYVILLE, CA - Symphogen A/S and Origen Therapeutics today announced a strategic collaboration to develop a transgenic chicken capable of producing human antibodies against a wide variety of disease targets. Origen will use its avian transgenic technology…

Betreffend: Symphogen

AGENDIA Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board

5 März 2009 – HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Dr. Albert A. (Al) Luderer to its Supervisory Board. Dr. Luderer has more than 30 years of experience in in vitro medical diagnostics,…

Betreffend: Agendia

BG MEDICINE Appoints Doug White as Executive Vice President & General Manager, Diagnostics

3 März 2009 – Waltham, Mass. – BG Medicine Inc. (BGM) today announced that Doug White has joined the organization as Executive Vice President & General Manager, Diagnostics.  In this newly created role, Mr. White will be responsible for the strategic direction and overall management of the company’s…

Betreffend: BG Medicine

AGENDIA Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer

18 Februar 2009 – HUNTINGTON BEACH, California, and AMSTERDAM, /PRNewswire/ - Findings Published in Peer-Reviewed Journal, Breast Cancer Research and Treatment Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonstrating the direct predictive ability of its breast…

Betreffend: Agendia

ACACIA PHARMA Appoints Ian Kent as Chairman

5 Februar 2009 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, today announced that Ian Kent has joined its Board of Directors as Non-executive Chairman. Ian has a wealth of corporate experience having acted as Chairman and Non-executive…

Betreffend: Acacia Pharma

IDEA AG - US Patent Office grants a new patent

5 Februar 2009 – Munich, Germany – IDEA AG today announced the granting of a new US patent (7,473,432) that covers the recently improved Transfersome® technology and the Company’s lead product, Diractin®, which is already approved in Switzerland and in the final stage (phase III) of clinical development…

Betreffend: IDEA

ABLYNX Announces Second Extension of its NANOBODY® Drug Discovery and Development Alliance

5 Februar 2009 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its drug discovery and development alliance with Novartis has been extended for another year. Under…

Betreffend: Ablynx

SYMPHOGEN Secures EUR 33 million Financing to Support Clinical Development of Antibody Products

4 Februar 2009 – COPENHAGEN, Denmark - Symphogen A/S today announced the closing of a € 33 million (approximately U.S. $44 million) financing. Existing investors participated in the round, which was led by Essex Woodlands Health Ventures. The financing will be used to mature the company’s product…

Betreffend: Symphogen

ABLYNX Receives EUR 3 million in Milestone Payments

3 Februar 2009 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it will receive milestone payments totalling €3 million from Boehringer Ingelheim triggered as…

Betreffend: Ablynx

PIERIS reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist

3 Februar 2009 – Expansion of management team announced to support program success Freising-Weihenstephan, Germany – Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development…

Betreffend: Pieris Pharmaceuticals Inc.

YMPHOGEN Adds Receptor’s Pan-HER Ligand Trap Technology to Diversify Recombinant Polyclonal Antibody

29 Januar 2009 – COPENHAGEN, Denmark and PALO ALTO, Calif., U.S. -  Symphogen A/S and Receptor BioLogix, Inc ,( Receptor). announced today that Symphogen has acquired the technology and programs of Receptor BioLogix. Symphogen is a leader in developing recombinant polyclonal antibodies, a new class…

Betreffend: Symphogen

AMT: Glybera® Lowers Pancreatitis Incidence Significantly

28 Januar 2009 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today during the Phacilitate Cell & Gene Therapy Forum new data showing that one treatment of its lead product Glybera® results in a long term significant…

AMT CEO Ronald Lorijn Steps Down - Sander van Deventer Interim CEO

22 Januar 2009 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that Dr. Ronald H.W. Lorijn will for personal reasons retire as chief executive officer, effective February 1, 2009. Prof. Sander van Deventer,…

ABLYNX Expands its Musculoskeletal Portfolio by Taking P&G Pharmaceutical’s Programme In-House

20 Januar 2009 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, has expanded its musculoskeletal research portfolio by transferring in-house full ownership of a bone disorder R&D…

Betreffend: Ablynx

ABLYNX announces Technical Advances in its NANOBODY® Platform

14 Januar 2009 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today two significant advances achieved with its Nanobody® platform. In the first, it has shown that anti-viral…

Betreffend: Ablynx

Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines

12 Januar 2009 – Collegeville, Pa., & Hoersholm, Denmark — Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Santaris Pharma today announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma’s…

Betreffend: Santaris Pharma

ABLYNX Strengthens Management Team with the Appointment of Dr Debbie Law as Chief Scientific Officer

8 Januar 2009 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has appointed Dr Debbie Law, as its Chief Scientific Officer. Dr Law has over thirteen years…

Betreffend: Ablynx

Acacia Pharma completes clinical trial with APD 405 for nausea & vomiting

6 Januar 2009 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, has successfully completed its first clinical trial, a Phase I study of its lead product candidate APD 405. Acacia is one of the few companies focused on supportive care,…

Betreffend: Acacia Pharma

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare ist ein spezialisierter europäischer Healthcare-Investor und verwaltet über 1,4 Mrd. EUR (1,5 Mrd. USD) in zwei Fondsstrategien: Private Equity sowie Venture & Growth Capital. Der Private Equity-Fonds von Gilde Healthcare investiert in profitable europäische Gesundheitsunternehmen im Mittelstand und konzentriert sich auf die Benelux- und DACH- Region. Der Private-Equity-Fonds richtet sich an Leistungserbringer und Gesundheitsdienstleister sowie Anbieter von Medizinprodukten im Gesundheitswesen. Der Venture & Growth Capital Fonds von Gilde Healthcare investiert in Medizintechnik, digitale Gesundheit und Therapeutika. Die Venture & Growth-Unternehmen sind in Europa und Nordamerika ansässig.

Investment Philosophie

Gilde Healthcare beteiligt sich an schnell wachsenden, innovativen Unternehmen, die bessere Pflege bei niedrigeren Kosten erbringen.

  • Home
  • Portfolio
  • Team
  • Neuigkeiten
  • Kontakt
  • Impressum
  • Privacy Policy